Literature DB >> 33270944

A review of the pivotal role of cardiac MRI in mitral valve regurgitation.

Kushani Gajjar1, Kartikeya Kashyap1, Jayshiv Badlani2, Ronald B Williams2, Robert W W Biederman1,2,3,4.   

Abstract

Cardiac imaging is the cornerstone of defining the etiology, quantification, and management of mitral regurgitation (MR). This continues to be even more so the case with emerging transcatheter techniques to manage MR. Transthoracic echocardiography remains the first-line imaging modality to assess MR but has limitations. Cardiac MRI(CMR) provides the advantages of quantitative nonvisual estimation, 3D volumetric data, late gadolinium, T1, and extracellular volume measurements to comprehensively assess mitral valvular pathology, cardiac remodeling, and the prognostic impact of therapies. This review describes the superiority, technical aspects and growing evidence behind CMR, and lays the roadmap for the future of CMR in MR.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  CMR; MR; cardiac MRI; mitral regurgitation; mitral valve

Year:  2020        PMID: 33270944     DOI: 10.1111/echo.14941

Source DB:  PubMed          Journal:  Echocardiography        ISSN: 0742-2822            Impact factor:   1.724


  2 in total

1.  Machine Learning Patient-Specific Prediction of Heart Failure Hospitalization Using Cardiac MRI-Based Phenotype and Electronic Health Information.

Authors:  Aidan K Cornhill; Steven Dykstra; Alessandro Satriano; Dina Labib; Yoko Mikami; Jacqueline Flewitt; Easter Prosio; Sandra Rivest; Rosa Sandonato; Andrew G Howarth; Carmen Lydell; Cathy A Eastwood; Hude Quan; Nowell Fine; Joon Lee; James A White
Journal:  Front Cardiovasc Med       Date:  2022-06-16

Review 2.  Rationale and clinical applications of 4D flow cardiovascular magnetic resonance in assessment of valvular heart disease: a comprehensive review.

Authors:  Miroslawa Gorecka; Malenka M Bissell; David M Higgins; Pankaj Garg; Sven Plein; John P Greenwood
Journal:  J Cardiovasc Magn Reson       Date:  2022-08-22       Impact factor: 6.903

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.